Provided By GlobeNewswire
Last update: Jul 9, 2025
The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated
Read more at globenewswire.comNASDAQ:TNXP (7/25/2025, 3:36:07 PM)
49.31
+4.59 (+10.26%)
Find more stocks in the Stock Screener